BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas 2020;49:863-81. [PMID: 32675783 DOI: 10.1097/MPA.0000000000001597] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 48.0] [Reference Citation Analysis]
Number Citing Articles
1 Elks W, Li JR, Zajack A, Horner L, Ikeda A, St Hill C, Scheidler M, Chang S. Pancreaticoduodenectomy in 11-year-old male with a non-functional pancreatic neuroendocrine tumor. Journal of Pediatric Surgery Case Reports 2022. [DOI: 10.1016/j.epsc.2022.102516] [Reference Citation Analysis]
2 Javed AA, Pulvirenti A, Zheng J, Michelakos T, Sekigami Y, Razi S, McIntyre CA, Thompson E, Klimstra DS, Deshpande V, Singhi AD, Weiss MJ, Wolfgang CL, Cameron JL, Wei AC, Zureikat AH, Ferrone CR, He J; Pancreatic Neuroendocrine Disease Alliance (PANDA). A novel tool to predict nodal metastasis in small pancreatic neuroendocrine tumors: A multicenter study. Surgery 2022:S0039-6060(22)00616-X. [PMID: 36192215 DOI: 10.1016/j.surg.2022.08.022] [Reference Citation Analysis]
3 Mohindroo C, McAllister F, De Jesus-Acosta A. Genetics of Pancreatic Neuroendocrine Tumors. Hematol Oncol Clin North Am 2022:S0889-8588(22)00073-9. [PMID: 36154786 DOI: 10.1016/j.hoc.2022.07.005] [Reference Citation Analysis]
4 Komarnicki P, Musiałkiewicz J, Stańska A, Maciejewski A, Gut P, Mastorakos G, Ruchała M. Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future. JCM 2022;11:5542. [DOI: 10.3390/jcm11195542] [Reference Citation Analysis]
5 Puhr-westerheide D, Ricke J. Interventionelle Therapie bei endokrinen und neuroendokrinen Tumoren. Onkologie 2022;28:667-678. [DOI: 10.1007/s00761-022-01200-0] [Reference Citation Analysis]
6 Hackeng WM, Assi HA, Westerbeke FH, Brosens LA, Heaphy CM. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.05.007] [Reference Citation Analysis]
7 Heaphy CM, Singhi AD. The Diagnostic and Prognostic Utility of Incorporating DAXX, ATRX, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of Pancreatic Neuroendocrine Tumors (PanNETs). Hum Pathol 2022:S0046-8177(22)00189-7. [PMID: 35872157 DOI: 10.1016/j.humpath.2022.07.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Torbenson M, Venkatesh SK, Halfdanarson TR, Navin PJ, Kamath P, Erickson LA. Primary Neuroendocrine Tumors and Primary Neuroendocrine Carcinomas of the Liver: A Proposal for a Multidiscipline Definition. Hum Pathol 2022:S0046-8177(22)00174-5. [PMID: 35809684 DOI: 10.1016/j.humpath.2022.07.001] [Reference Citation Analysis]
9 Ranallo N, Iamurri AP, Foca F, Liverani C, De Vita A, Mercatali L, Calabrese C, Spadazzi C, Fabbri C, Cavaliere D, Galassi R, Severi S, Sansovini M, Tartaglia A, Pieri F, Crudi L, Bianchini D, Barone D, Martinelli G, Frassineti GL, Ibrahim T, Calabrò L, Berardi R, Bongiovanni A. Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis. Cancers 2022;14:3231. [DOI: 10.3390/cancers14133231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hope TA, Pavel M, Bergsland EK. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? J Clin Oncol 2022;:JCO2200176. [PMID: 35649195 DOI: 10.1200/JCO.22.00176] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Thompson O, Hall L, Roberts K, Bradley E, Powell-brett S, Pande R, Shah T. Survival benefit of pancreatic enzyme replacement therapy in patients undergoing treatment of pancreatic neuroendocrine tumours. HPB 2022. [DOI: 10.1016/j.hpb.2022.06.001] [Reference Citation Analysis]
12 Li YL, Cheng ZX, Yu FH, Tian C, Tan HY. Advances in medical treatment for pancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(20): 2163-2175 [DOI: 10.3748/wjg.v28.i20.2163] [Reference Citation Analysis]
13 Dai M, Mullins CS, Lu L, Alsfasser G, Linnebacher M. Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(5): 383-396 [DOI: 10.4240/wjgs.v14.i5.383] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Bartolomei M, Berruti A, Falconi M, Fazio N, Ferone D, Lastoria S, Pappagallo G, Seregni E, Versari A. Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. Cancers (Basel) 2022;14:2501. [PMID: 35626105 DOI: 10.3390/cancers14102501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Canakis A, Lee LS. Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Endosc 2022; 14(5): 267-290 [DOI: 10.4253/wjge.v14.i5.267] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Concors SJ, Maxwell JE. Neuroendocrine hepatic metastatic disease: the surgeon's perspective. Abdom Radiol (NY) 2022. [PMID: 35476146 DOI: 10.1007/s00261-022-03515-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Panchal R, Cottrell-Cumber S, Anderson CD. Localization of VIPoma with NETSpot. Am Surg 2022;:31348221086797. [PMID: 35435004 DOI: 10.1177/00031348221086797] [Reference Citation Analysis]
18 Mansfield BA, Halfdanarson TR, Hallemeier CL. Dramatic Response of a Pancreas Neuroendocrine Tumor Liver Metastasis to High-Dose Focal External Beam Radiotherapy: A Case Report. Pancreas 2022;51:e72-3. [PMID: 35775645 DOI: 10.1097/MPA.0000000000002039] [Reference Citation Analysis]
19 Holmager P, Langer SW, Kjaer A, Ringholm L, Garbyal RS, Pommergaard HC, Hansen CP, Federspiel B, Andreassen M, Knigge U. Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Curr Treat Options Oncol 2022. [PMID: 35362798 DOI: 10.1007/s11864-022-00969-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Galgano SJ, Morani AC, Gopireddy DR, Sharbidre K, Bates DDB, Goenka AH, Arif-Tiwari H, Itani M, Iravani A, Javadi S, Faria S, Lall C, Bergsland E, Verma S, Francis IR, Halperin DM, Chatterjee D, Bhosale P, Yano M. Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists. Abdom Radiol (NY) 2022. [PMID: 35244755 DOI: 10.1007/s00261-022-03466-9] [Reference Citation Analysis]
21 van Treijen MJC, Schoevers JMH, Heeres BC, van der Zee D, Maas M, Valk GD, Tesselaar MET. Defining disease status in gastroenteropancreatic neuroendocrine tumors: Choi-criteria or RECIST? Abdom Radiol (NY) 2022;47:1071-81. [PMID: 34989825 DOI: 10.1007/s00261-021-03393-1] [Reference Citation Analysis]
22 Zhang D, Lu L, Zhu H, Xiao Y, Han X, Du S, Xue H, Liu Q, Zhu Z, Hu M, Zhai X, Xing X, Lu Z, Reimondo G. Somatostatin Treatment for Ectopic ACTH Syndrome due to Pancreatic Neuroendocrine Tumors: Review of the Literature. International Journal of Endocrinology 2022;2022:1-10. [DOI: 10.1155/2022/6283706] [Reference Citation Analysis]
23 Galgano SJ, Iravani A, Bodei L, El-haddad G, Hofman MS, Kong G. Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response— AJR Expert Panel Narrative Review. American Journal of Roentgenology. [DOI: 10.2214/ajr.21.27159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
24 Fandel TM, Blevins LS. Growth Hormone-Releasing Hormone-Secreting Neuroendocrine Tumors. Acromegaly 2022. [DOI: 10.1007/978-3-031-16258-9_2] [Reference Citation Analysis]
25 Majumder S, Halfdanarson TR, Berger CK, Foote PH, Cao X, Mcglinch MC, Gysbers BJ, de La Fuente J, Robran MJ, Doering KA, Burger KN, Bamlet WE, Oberg AL, Mahoney DW, Graham RP, Taylor WR, Petersen GM, Kisiel JB. Discovery and Validation of Methylated DNA Markers From Pancreatic Neuroendocrine Tumors. Gastro Hep Advances 2022;1:409-416. [DOI: 10.1016/j.gastha.2022.01.006] [Reference Citation Analysis]
26 Mathew A, Führer D, Lahner H. Sunitinib-Induced Hypothyroidism and Survival in Pancreatic Neuroendocrine Tumors. Horm Metab Res 2021;53:794-800. [PMID: 34891209 DOI: 10.1055/a-1658-3077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Refardt J, Hofland J, Wild D, Christ E. New Directions in Imaging Neuroendocrine Neoplasms. Curr Oncol Rep 2021;23:143. [PMID: 34735669 DOI: 10.1007/s11912-021-01139-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Egal ESA, Jacenik D, Soares HP, Beswick EJ. Translational challenges in pancreatic neuroendocrine tumor immunotherapy. Biochim Biophys Acta Rev Cancer 2021;1876:188640. [PMID: 34695532 DOI: 10.1016/j.bbcan.2021.188640] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Touloupas C, Faron M, Hadoux J, Deschamps F, Roux C, Ronot M, Yevich S, Joskin J, Gelli M, Barbé R, Lamartina L, Tissot H, Scoazec JY, Malka D, Ducreux M, Baudin E, de Baère T, Tselikas L. Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience. Cancers (Basel) 2021;13:5366. [PMID: 34771531 DOI: 10.3390/cancers13215366] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
30 Li K, Yuan J, Li Y, Zhang H, Liu X, Ke N. Successful Neoadjuvant Chemotherapy for Small-Cell Neuroendocrine Carcinoma of the Pancreas: A Case Report. Front Oncol 2021;11:719422. [PMID: 34568048 DOI: 10.3389/fonc.2021.719422] [Reference Citation Analysis]
31 Khanna A, Cianci N, Abbas Shah H, Goel A, Jebril A, Chauhan J, Pipe M, Shetty S, Weston C, Venkataraman H, Smith S, Vickrage S, Kemp‐blake J, Shah T. Telotristat in the management of Carcinoid diarrhoea – A real world experience of patients from ENETs centre of excellence in Neuroendocrine tumours. GastroHep 2021;3:291-297. [DOI: 10.1002/ygh2.491] [Reference Citation Analysis]
32 Liu CH, Grodzinski P. Nanotechnology for Cancer Imaging: Advances, Challenges, and Clinical Opportunities. Radiol Imaging Cancer 2021;3:e200052. [PMID: 34047667 DOI: 10.1148/rycan.2021200052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Zheng K, Liu T, Zhao J, Meng P, Bian Y, Ni C, Wang H, Pan Y, Wu S, Jiang H, Jin G. Mutational landscape and potential therapeutic targets for sporadic pancreatic neuroendocrine tumors based on target next-generation sequencing. Exp Ther Med 2021;21:415. [PMID: 33747156 DOI: 10.3892/etm.2021.9859] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Ricci C, Lamberti G, Ingaldi C, Mosconi C, Pagano N, Alberici L, Ambrosini V, Manuzzi L, Monari F, Malvi D, Rosini F, Minni F, Campana D, Casadei R. Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials. Cancers (Basel) 2021;13:358. [PMID: 33561087 DOI: 10.3390/cancers13020358] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
35 Panzuto F, Maccauro M, Campana D, Faggiano A, Massironi S, Pusceddu S, Spada F, Ferone D, Modica R, Grana CM, Ferolla P, Rinzivillo M, Badalamenti G, Zatelli MC, Gelsomino F, De Carlo E, Bartolomei M, Brizzi MP, Cingarlini S, Versari A, Fanciulli G, Arvat E, Merola E, Cives M, Tafuto S, Baldari S, Falconi M. Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet). J Endocrinol Invest 2021;44:989-94. [PMID: 32803662 DOI: 10.1007/s40618-020-01393-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]